Abstract 188P
Background
Due to its complex pathophysiology, several comorbidities have to be taken in count in clinical decision-making process for hepatocellular carcinoma (HCC) patients. The aim of the present work was to investigate the potential prognostic role of metformin, aspirin, statins and insulin use in a cohort of advanced HCC patients who received Lenvatinib or atezolizumab plus bevacizumab as first- line treatment.
Methods
The population included HCC patients who received Atezolizumab plus Bevacizumab or Lenvatinib as first- line therapy. Univariate and multivariate analyses were performed by Cox proportional hazard to assess possible association between patients’ baseline characteristics and survival outcomes.
Results
730 patients with HCC were included in the analysis: 430 received Lenvatinib and 300 received Atezolizumab plus Bevacizumab. In both the treatment arms, no statistically differences in terms of OS and PFS were highlighted in patients who make chronic use of statin, aspirin or insulin compared to those who do not. In the Atezolizumab plus Bevacizumab arm, 50 (16.5%) patients were recorded to chronically use metformin. Patients in metformin group showed significantly shorter OS compared to patients in no-metformin group [respectively, 14.9 months (95% CI 6.4-16.3) vs. 19.7 (95% CI 16.0-30.4); HR 1.9 (95% CI 1.1-3.2) p = 0.0248], as confirmed in multivariate analysis (HR 1.9; 95% CI, 1.1-3.1; p=0.0163). Moreover, patients in metformin group had significantly shorter PFS compared to patients in no-metformin group [respectively, 4.5 months (95% CI 2.9-14.2) vs. 5.8 (95% CI 4.1-34.0); HR 1.6 (95% CI 1.0-2.6) p = 0.0212], as confirmed in multivariate analysis (HR 1.7; 95% CI, 1.1-2.7; p=0.0147).No statistically significant differences in terms of both OS and PFS were found between patients in metformin group and patients in no-metformin group in Lenvatinib arm.
Conclusions
The present study reports the first analysis focused on the role of metformin in a large double cohort of patients affected by advanced HCC who received Lenvatinib or Atezolizumab plus Bevacizumab, thus showing a negative prognostic role of metformin use in the Atezolizumab plus Bevacizumab group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract